Evaluation of an Electro-stimulator for the Treatment of Xerostomia

Xerostomia Clinical Trial

— GenNarino  

Official title:

Safety and Performance Evaluation of an Electro-stimulator Mounted on an Intra-oral Removable Appliance (Saliwell GenNarino) for the Treatment of Xerostomia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00509808
• Other study ID #: 1-Wolff
• Status: Completed
• Phase: Phase 4
• First received: July 31, 2007
• Last updated: April 5, 2010
• Start date: January 2007
• Est. completion date: April 2010

Study information

• Verified date: April 2010
• Source: Saliwell Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review CommitteeColombia: Institutional Review BoardFinland: Ethics CommitteeGermany: Ethics CommissionIsrael: Ministry of HealthItaly: Ethics CommitteeSpain: Ethics CommitteeSweden: Institutional Review BoardTurkey: Ethics CommitteeUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This is a multinational trial, aimed at testing the safety and performance of a electrostimulating device ("GenNarino") to treat dry mouth, over one year. The design is as follows:

• Multi-center, double blind, sham (placebo) controlled, about 10 xerostomia patients per center

• Patients receive a GenNarino (and its remote control) that is programmed for one month sham and one month active mode (the order of which is randomly assigned), and thereafter 9 months at the active mode (divided in period of 3 months, the order of each is randomly assigned at wearing GenNarino for 1, 5 or 10 minutes at a time).

Study hypothesis: Gennarino will lead to significant symptomatic improvement

• At the clinic: monthly examinations at the first 2 months, and then every 3 months, including whole saliva collection and questionnaire; at the first visit impression taking for GenNarino preparation

Description:

The clinical trial, titled "Safety and performance evaluation of an electro-stimulator mounted on an intra-oral removable appliance (GenNarino) for the treatment of xerostomia" is a prospective, randomized, double-blind, sham-controlled multi-center trial, followed by an open-label study. Study subjects are patients with xerostomia. The purpose of the trial is to test the safety and efficacy of electrostimulation using the GenNarino device.

The primary endpoint is significant symptomatic improvement, and the secondary ones, increased salivary output and event free use (no adverse side-effects). The clinical follow-up consists of periodic clinical examinations.

In this clinical trial the use of the device is compared between active vs. sham mode for one month each in a double-blind design (Stage I). Thereafter, at Stage II the xerostomia relieving effect of the active device is assessed in an open label design for additional 6 months. Clinic- and home-based questionnaires and whole saliva collections are performed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: April 2010
• Est. primary completion date: April 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The patient must be at least 18 years of age.

2. The patient must have clinical symptoms of xerostomia (dry mouth) due to

• Primary or secondary Sjögren's syndrome

• Medication intake

• Head and neck radiation with survival expectancy of more than one year

• Chronic graft vs. host disease with survival expectancy of more than one year

3. Patients are requested not to take systemic sialogogues during the first 2 months of the study (when active is tested vs. sham)

4. Female patients of child bearing potential must have a negative pregnancy test within twenty-four hours of enrollment.

5. The patient must understand and consent in writing to the procedure.

6. The patient agrees to undergo all examinations and clinical evaluations planned for the study.

Exclusion Criteria:

1. Active HIV or HCV infection

2. Severe systemic disease

3. Known allergy to materials similar to be used in the investigational product

4. Known mental disease

5. Presence of depression, by positive answers to both the following questions:

• "During the past month have you often been bothered by feeling down, depressed or hopeless?"

• "During the past month have you often been bothered by little interest or pleasure in doing things?"

6. Patients wearing other active implants like pacemaker or defibrillator

7. Patients with poor oral hygiene

8. Patients whose oral anatomical characteristics precludes the insertion of the device

9. Patients who are unable or unwilling to cooperate with study procedures.

10. Pregnancy

11. Presence of erosive or ulcerative oral lesions, which are chronic or recurrent, such as erosive lichen planus, RAS, eryth. Candidosis, and of suspected pre-malignant or malignant lesions

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Xerostomia

Intervention

Device:
• Electrostimulation
1st month GN wearing (activated or sham mode) 2nd month wearing (opposite mode) 3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes 6th - 8th month: activated GN wearing for 1, 5 or 10 minutes 9th - 11th month: activated GN wearing for 1, 5 or 10 minutes

Locations

Country	Name	City	State
Finland	Helsinki University Central Hospital and University of Helsinki	Helsinki

Sponsors (15)

Lead Sponsor	Collaborator
Saliwell Ltd.	Charite University, Berlin, Germany, Hebrew University of Jerusalem, Helsinki University, Hospital San Carlos, Madrid, Indiana University, Istanbul University, McGill University, Skane University Hospital, Universidad El Bosque, Bogotá, Universidad Nacional Autonoma de Mexico, Universita degli Studi di Palermo, University of Brasilia, University of Kentucky, University of Zagreb

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Significant symptomatic improvement		1 year	No
Secondary	1- Increased salivary output 2- Event free use (no adverse side-effects)		1 year	No